https://www.selleckchem.com/pr....oducts/Mizoribine.ht
Among clinicians prescribing to new patients without an in-person examination, 5.5 % reported difficulties with buprenorphine induction, most commonly withdrawal symptoms. Telehealth practices and prescribing to new patients without an in-person examination were adopted by DATA-waivered clinicians during the first six months of COVID-19. Permanent adoption of these authorities may enable expanded access to buprenorphine treatment. Telehealth practices and prescribing to new patients without an in-person examination were adopted by DA
Like
Comment
Share
